Ciladopa

Ciladopa
	File:Ciladopa.png
Systematic (IUPAC) name
	2-{4-[(2S)-2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]piperazin-1-yl}cyclohepta-2,4,6-trien-1-one
Clinical data
Legal status	Uncontrolled;
Routes of; administration	Oral
Identifiers
CAS Registry Number	80109-27-9
ATC code	None
PubChem	CID 133371
ChemSpider	117659
UNII	D09L486R3J 7px
ChEMBL	CHEMBL2110793
Chemical data
Formula	C21H26N2O4
Molecular mass	370.44 g/mol
	SMILES O=C3/C=C\C=C/C=C3/N2CCN(C[C@@H](O)c1ccc(OC)c(OC)c1)CC2;

</th></tr>

Ciladopa (AY-27,110) is a dopamine agonist with a similar chemical structure to dopamine.^[1] It was under investigation as an antiparkinsonian agent but was discontinued due to concerns of tumorogenesis in rodents.^[2]^[3]^[4]^[5]

References

^ Voith K (1985). "The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats". Psychopharmacology 85 (4): 405–9. PMID 3927334. doi:10.1007/BF00429654.
^ Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). "Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug". Neuropharmacology 25 (9): 973–9. PMID 3774130. doi:10.1016/0028-3908(86)90190-5.
^ Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). "A double-blind evaluation of ciladopa in Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society 2 (3): 211–7. PMID 3332914. doi:10.1002/mds.870020308.
^ Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (May 1987). "Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa". Neurology 37 (5): 863–5. PMID 3574692. doi:10.1212/wnl.37.5.863.
^ Lang AE (August 1987). "Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"". The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 14 (3 Suppl): 474–82. PMID 3315148.